Knight Therapeutics
A Canadian specialty pharmaceutical company that acquires, licenses, and commercializes innovative medicines in Canada and selected international markets.
Last updated August 22, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Knight Therapeutics Inc. is a Canadian specialty pharmaceutical company headquartered in Montreal, Quebec. The company focuses on acquiring, licensing, registering, and commercializing innovative pharmaceutical products rather than conducting the full spectrum of early-stage drug discovery itself. Its principal commercial orientation is Canada, supplemented by selected Latin American markets where it works to introduce medicines addressing significant or insufficiently served medical needs. Knight was established in 2014 in connection with the sale of most of the operating assets of Paladin Labs to Endo Pharmaceuticals. Jonathan Ross Goodman, who had co-founded Paladin Labs, led the new company. As part of the transaction, Knight was spun off to Paladin shareholders and received rights to Impavido, a treatment for leishmaniasis. The formation therefore gave Knight both a new corporate identity and continuity with Paladin's specialty-pharmaceutical commercialization model. The company's historical roots extend to 1995, when Goodman and Mark Beaudet founded Paladin Labs. Paladin built a business around obtaining rights to pharmaceutical products from international developers, securing regulatory approvals, and marketing those products in Canada. Its activities included licensing, acquisitions, and the development of a sales and distribution platform for specialty medicines. Knight inherited this general strategy after the Paladin transaction and adapted it for a broader Canada-and-Latin-America footprint. Knight's portfolio has included medicines in areas such as pain and gastrointestinal disorders, ophthalmology, women's health, oncology, infectious diseases, neurology, rare diseases, edema, and opioid-use-disorder treatment. Products identified in public descriptions of the business include Movantik for opioid-induced constipation, Probuphine, a subdermal implant for opioid dependence, Impavido for leishmaniasis, and Burinex for edema associated with congestive heart failure, cirrhosis of the liver, and renal disease. Product rights, regulatory status, and commercial availability can vary by country and over time. The company's operating model depends on partnerships with international biopharmaceutical companies and on local regulatory and commercial capabilities. In Canada, this includes pursuing Health Canada authorization and then supplying medicines to healthcare providers, institutions, and patients through appropriate distribution channels. In Latin America, Knight has sought to commercialize products across a group of selected national markets, using regional infrastructure and local regulatory processes. Knight is listed on the Toronto Stock Exchange under the symbol GUD. Public descriptions have characterized it as a specialty-pharmaceutical company with a portfolio spanning multiple therapeutic areas and a workforce of more than 700 people as of 2020. Its positioning is that of a focused commercialization partner for innovative medicines, especially products that may be too specialized for a broad consumer-pharmaceutical model but have meaningful clinical or market potential in Canada and selected international territories.
History
Knight Therapeutics emerged from the corporate reorganization of Paladin Labs, a Canadian specialty-pharmaceutical company founded in 1995 by Jonathan Ross Goodman and Mark Beaudet. Paladin's business model centered on obtaining rights to medicines developed by other pharmaceutical companies, obtaining the regulatory approvals required for Canada, and commercializing the products through a focused specialty-sales organization. This approach allowed the company to build a portfolio without relying exclusively on internally discovered medicines. Paladin completed an initial public offering in 1995 at C$1.50 per share. Over the following years, it expanded through product licensing and acquisitions. Its history included the acquisition of Labopharm for C$20 million in 2011. In the same year, Paladin attempted to acquire Afexa Life Sciences, but Valeant Pharmaceuticals submitted a higher bid. These transactions illustrated the competitive acquisition environment in the Canadian pharmaceutical sector and Paladin's strategy of using acquisitions to broaden its portfolio. Also in 2011, Jonathan Ross Goodman was seriously injured in a cycling accident and temporarily relinquished the chief executive position. Mark Beaudet assumed the role while Goodman recovered. Public descriptions of the event state that Goodman suffered a traumatic brain injury but later almost fully recovered. The episode was a temporary leadership interruption rather than a change in the company's long-term strategic identity. A major transformation occurred in 2014, when Endo Pharmaceuticals acquired most of Paladin Labs' assets. The transaction was described as having a value of approximately US$3 billion, or C$151 per share in the cited account. Rather than disappearing entirely, the Paladin-related business was reorganized: Knight Therapeutics was spun off to Paladin shareholders and was led by Goodman. Knight received rights to Impavido, a medicine used to treat leishmaniasis, and continued operating in the specialty-pharmaceutical field. The new company retained the core logic of Paladin's model while defining a more explicitly international target area. Knight focused on acquiring or in-licensing innovative products for Canada and selected Latin American markets. Its responsibilities included working through local regulatory processes, including Health Canada authorization for Canadian products, and building commercial access after approval. The company generally did not present itself as a conventional research-based pharmaceutical enterprise engaged primarily in initial drug discovery; instead, its role was to identify promising products and make them available in territories where it could add regulatory, commercial, and distribution expertise. Public descriptions of Knight's portfolio have included pain and gastrointestinal medicines, ophthalmic products, women's-health products, oncology therapies, infectious-disease treatments, neurology products, and medicines for rare diseases. Specific products mentioned include Movantik for opioid-induced constipation, Probuphine for opioid dependence, Impavido for leishmaniasis, and Burinex for edema associated with heart failure, cirrhosis, and renal disease. The commercial status of individual products may change by jurisdiction and over time. In 2016, reports suggested that Endo might consider selling Paladin Labs back to Knight Therapeutics for less than Endo had paid in the 2014 transaction. The reported possibility underscored the continuing connection between the two businesses, but the available reference does not establish that the proposed sale took place. By 2020, Knight was described as commercializing dozens of innovative pharmaceuticals in Canada and ten Latin American countries, with a workforce exceeding 700 employees. The company remains a Toronto Stock Exchange-listed specialty pharmaceutical business operating from Montreal.
- 2016
Possible reacquisition of Paladin is reported
[1]Media reports suggest Endo may be considering selling Paladin Labs back to Knight Therapeutics, although the reference does not confirm that the transaction occurred.
- 2014
Knight Therapeutics is created through the Paladin reorganization
[1]After Endo Pharmaceuticals acquires most of Paladin Labs, Knight Therapeutics is spun off to Paladin shareholders and receives rights to Impavido.
- 2011
Paladin acquires Labopharm
[1]Paladin Labs acquires Labopharm for C$20 million.
- 1995
Paladin Labs is founded
[1]Jonathan Ross Goodman and Mark Beaudet establish Paladin Labs, the predecessor business whose specialty-pharmaceutical model later informs Knight Therapeutics.
- 1995
Paladin Labs completes its IPO
[1]Paladin Labs goes public at C$1.50 per share.
Products and positioning
A specialty pharmaceutical commercialization platform focused on acquiring or in-licensing innovative medicines and bringing them to patients in Canada and selected Latin American markets, particularly in therapeutic areas with unmet or underserved needs.
Infectious-disease medicine
Impavido
Impavido is a treatment for leishmaniasis, a parasitic infectious disease. Rights to the medicine formed part of the assets transferred to Knight Therapeutics when the company was spun off during the 2014 transaction involving Endo Pharmaceuticals and Paladin Labs. Its inclusion gave Knight an established specialty product in an infectious-disease area with specific medical needs.
Gastrointestinal medicine
Movantik
Movantik is used to treat opioid-induced constipation, a gastrointestinal complication associated with opioid therapy. It represents Knight's participation in specialty supportive care, where the commercial opportunity is linked to a defined patient population and an adverse effect of widely used prescription medicines.
Opioid-use-disorder treatment
Probuphine
Probuphine is a subdermal implant used in the treatment of opioid dependence. The product fits Knight's focus on specialty medicines and clinically defined patient populations, while also placing the company in the treatment area associated with opioid-use disorder.
Diuretic and cardiovascular-support medicine
Burinex
Burinex is associated with the management of edema linked to congestive heart failure, cirrhosis of the liver, and renal disease. Its inclusion in Knight's described portfolio illustrates the company's coverage of established specialty and hospital-oriented medicines alongside newer innovative products.
Brand decisions
2016
A possible sale of Paladin Labs back to Knight is reportedM&ABackground
After Endo acquired most of Paladin Labs, reports indicated that Endo might later consider disposing of the business.
Action taken
A possible sale of Paladin Labs to Knight Therapeutics was reported, potentially at a value below Endo's original purchase price.
Aftermath
The available reference describes this as a rumor or report and does not confirm that a transaction was completed.
2014
Endo Pharmaceuticals acquires most of Paladin Labs' assetsM&ABackground
Paladin Labs had developed a Canadian specialty-pharmaceutical platform through product commercialization and acquisitions. Endo Pharmaceuticals pursued a transaction for most of the business.
Action taken
Endo Pharmaceuticals acquired most of Paladin Labs' assets. Knight Therapeutics was spun off to Paladin shareholders and received rights to Impavido.
Aftermath
Knight became a separate public specialty-pharmaceutical company led by Jonathan Ross Goodman and continued the predecessor's general commercialization model in Canada and selected international markets.
Reported transaction value. Approximately US$3 billion, described in the reference as C$151 per share (2014)
2011
Paladin Labs acquires LabopharmM&ABackground
Paladin Labs was expanding its specialty-pharmaceutical portfolio through acquisitions and licensing. Labopharm represented an opportunity to add pharmaceutical assets to the predecessor company's platform.
Action taken
Paladin Labs completed the acquisition of Labopharm for C$20 million.
Aftermath
The acquisition became part of the corporate and commercial history preceding the creation of Knight Therapeutics.
Acquisition value. C$20 million transaction (2011)
Recent events
Crescita announces a $3.5 million credit facility[3]
Reported:
Crescita Therapeutics announced a $3.5 million revolving demand operating credit facility with the Royal Bank of Canada after repaying its Knight Therapeutics loan. The facility's closing remained subject to granting RBC a first-ranking charge over Crescita's receivables and inventories.
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/knight-therapeutics · Editorial policy · How profiles are compiled